Navigation Links
PharmaNova Fuels Business Growth with Lacerta Bio Partnership
Date:3/7/2011

VICTOR, N.Y., March 7, 2011 /PRNewswire/ -- PharmaNova, Inc. (PharmaNova) announces an agreement with Lacerta Bio, Inc. whereby Lacerta Bio's experienced team of business development professionals will supplement PharmaNova's team in the U.S. and U.K. to support its 2011 business growth and expansion initiatives. Emphasis will be on widening PharmaNova's partnering base for its innovative, nanoparticle technology, NovaSperse(SM), including existing NovaSperse(SM) new product opportunities and other projects that are available from PharmaNova for licensing and further development by third parties.

"We are delighted to be working with Lacerta Bio," said Rodney Brown, President of PharmaNova. "We have known both of the Lacerta Bio Managing Partners for several years, and are confident that working together, we can rapidly expand both our out-licensing and Fee-For-Service initiatives."

NovaSperse(SM), PharmaNova's proprietary, high drug load nanoparticle technology, utilizes minimal excipients and does not require complex equipment or processes. The NovaSperse(SM) process can be used to improve the solubility and enhance the delivery and pharmacokinetic properties of formulations in ophthalmics, dermatology, parenterals, and for other routes of administration.

"We have followed the progress made by PharmaNova over the past few years," said Dr. Anand R. Baichwal, Managing Partner of Lacerta Bio. "The NovaSperse(SM) technology is an excellent approach for rapidly developing new formulations with real therapeutic benefits, and we are excited to be a part of it."

About PharmaNova

PharmaNova is a privately held pharmaceutical company, which sub-licenses cutting-edge drug technology with its pioneering origins at the University of Rochester, and which develops and partners valuable new products to address underserved medical needs. Our products are created by re-positioning and enhancing the properties of known drugs using our proprietary NovaSperse(SM) nanoparticle drug delivery technology. A major additional component of our business is contractual formulation development work applying NovaSperse(SM) technology to support the repositioning and enhancement of client-owned products and compounds.

For more information, please visit http://www.pharmanovaco.com or contact Rodney A. Brown, President, PharmaNova, Inc. at +1-585-413-4721.

About Lacerta Bio

Lacerta Bio, Inc. is a business development and licensing consultancy for life sciences and other healthcare-related companies. Located in New York, Lacerta Bio assists life sciences companies and their investors identify, assess, and execute business development and licensing opportunities. The company also provides consulting on market opportunity assessments, competitive intelligence, pipeline analysis, interim business development management, and business plan and presentation development.

For more information, please visit http://www.lacertabio.com or contact Lacerta Bio, Inc. at +1 718 395 9371.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE PharmaNova, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
2. Paper or Plastic? Technology Fuels Gift Card Popularity and Access as an Alternative to Cash Incentives and Gifts
3. Kronos Announces First Quarter Business Update and Financial Results
4. Growth Achieved in Spherixs Health Sciences Consulting Business
5. ImaRx Therapeutics Transitions Business Strategy
6. Argonauta Communications Certified as Women-Owned Business by the Womens Business Enterprise National Council (WBENC)
7. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
8. Small Business Innovation Research Program Awards Grant to Biomoda
9. American Dairy Provides Business Update
10. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
11. Pharmos Issues Business Update on Dextofisopam Trial and Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected ... Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the position ... the end of 2018. Upon assuming the role of President and CEO on January ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
Breaking Medicine News(10 mins):